Current MRSA News and Events | Page 21

Current MRSA News and Events, MRSA News Articles.
Sort By: Most Relevant | Most Viewed
Page 21 of 21 | 825 Results
Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
Tigecycline, a first-in-class expanded broad spectrum antibiotic, produced a 74 percent cure rate in hospitalized patients with possibly life-threatening, complicated skin and skin structure infections. Tigecycline is currently in Phase 3 clinical trials and was developed by Wyeth Pharmaceuticals. (2004-05-23)

Outbreak of skin infections sheds light on risk factors for bacterial resistance
Scientists identify two major risk factors for community-acquired skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in a report published in the May 1 issue of The Journal of Infectious Diseases: previous antibiotic use and a genetic predisposition. (2004-04-22)

Linezolid is superior treatment for drug-resistant pneumonia
A relatively new drug called linezolid (commercially known as Zyvox) appears to be about 40 percent more effective in treating a deadly and increasingly prevalent form of antibiotic-resistant pneumonia than the conventionally used drug vancomycin, according to a team led by researchers at Washington University School of Medicine in St. Louis. (2004-03-02)

Lower social class linked to increased risk of postoperative MRSA infection
Results of a UK study in this week's issue of The Lancet suggest that people from the poorest socioeconomic backgrounds could be up to seven times more likely to get postoperative infection with meticillin-resistant Staphylococcus aureus (MRSA) than people from affluent social groups. (2004-02-26)

Death-defying approach devised by Penn scientists to prevent cell apoptosis
MSRA has been found to protect cells from reactive oxygen species. (2004-01-29)

Study finds new antibiotic effective for diabetic foot infections
A clinical trial involving 371 patients in eight countries shows that linezolid, a new antibiotic, is at least as effective as two older therapies for treating diabetic foot infections. The drug may be an important new agent for doctors treating infections that are increasingly caused by bacteria resistant to standard antibiotics, and that in severe cases may require amputation. (2004-01-15)

Increasing MRSA in California jails
According to a study published in the November 15 issue of Clinical Infectious Diseases, not only are the rates of MRSA increasing, but newer, drug-resistant strains are appearing at an increasingly fast pace outside the hospital environment. (2003-10-20)

Pfizer's ZYVOX(TM) more effective than vancomycin in treating complicated SSTIs caused by MRSA
Clinical cure rates were significantly better in patients treated with Pfizer's antibiotic ZYVOX™ (linezolid injection, tablets and for oral suspension) for complicated skin and soft tissue infections caused by known methicillin-resistant Staphylococcus aureus (MRSA) compared to patients treated with intravenous (IV) vancomycin. In the entire population studied, ZYVOX™ was as effective as all comparators. (2003-10-10)

Staph aureus bacteremia in ESRD patients associated with substantial illness and higher costs
End-stage renal disease patients who develop Staph aureus blood stream infections suffer substantial treatment costs and illness, according to new pharmacoeconomic studies that describe the clinical outcomes, health care resource use and infection-associated costs of Staph aureus bacteremia among prospectively identified hemodialysis-dependent patients. Moreover, ESRD patients with methicillin-resistant Staph aureus bacteremia have a higher risk of dying and incur higher treatment costs than patients with bacteremias caused by methicillin sensitive Staph aureus. (2003-09-17)

Linezolid improves survival rate in patients with hospital-acquired pneumonia
A study comparing two drugs regularly used to treat a common type of drug-resistant hospital-acquired pneumonia found that patients taking linezolid were twice as likely to survive as those taking vancomycin. The study was presented at the American Thoracic Society International Conference in Seattle. (2003-05-19)

Linezolid is better treatment for resistant pneumonia
A drug called linezolid is more successful at treating a deadly form of pneumonia than the standard treatment, vancomycin, according to data presented Jan. 30 at the 32nd Critical Care Congress of the Society of Critical Care Medicine in San Antonio. These results are based on data from two identical phase III clinical trials comparing linezolid to vancomycin in the treatment of pneumonia cases that develop in the hospital. (2003-01-30)

MRSA deaths on the rise
Infections due to MRSA seem to be an increasing cause of death in England and Wales, concludes a study in this week's BMJ. (2002-12-12)

A possible role for honey in the treatment of wounds
New research carried out by scientists at partner institutions UWIC (University of Wales Institute, Cardiff), University of Wales College of Medicine (UWCM) in Cardiff and the University of Waikato, New Zealand, has found sensitivity to honey of wound infecting bacteria. (2002-11-21)

New type of antiobiotic tackles hard-to-treat pediatric infections
Pediatricians have another weapon in their arsenal to fight infections that have shown resistance to common antibiotics. Study results showed that linezolid, a new type of antibiotic, is well-tolerated and as effective as the most common antibiotic, vancomycin, in treating infants and children with known or suspected gram-positive infections. (2002-10-26)

Superbug dynasties conquer the globe
The culprits behind antibiotic-resistant diseases now plaguing hospitals worldwide have been harboring a secret -- one that Rockefeller scientists have recently exposed. It seems these infectious microbes termed Staphylococcus aureus are not independent criminals working alone. Rather, they are members of only a few massive (2002-03-01)

New model of staph drug resistance implicates unlikely protein
Researchers at The Rockefeller University have established a new model to explain how the infectious (2001-08-21)

Widespread 'superbug' is expert at acquiring drug-resistance
One of the most widely disseminated strains of an antibiotic-resistant bacterium responsible for hundreds of infections in European hospitals can be traced back to the 1950s, according to researchers at The Rockefeller University. Using the molecular tool called DNA fingerprinting, they have shown that this persistent lineage of Staphylococcus aureus is an expert at acquiring resistance to antibiotics. (2001-08-08)

New Lancet review journal launched
August 2001 heralds the arrival of THE LANCET INFECTIOUS DISEASES, a new monthly specialty review journal from The Lancet Publishing Group. THE LANCET INFECTIOUS DISEASES (TLID) will provide researchers and clinicians with high-quality information about the latest developments in infectious disease medicine. (2001-07-31)

Early case of resistance to new antibiotic
A fast-track research letter published in this week's issue of THE LANCET describes the case of a patient whose infecting bacterium developed resistance to one of the new so-called bug-busting antibiotics. (2001-07-19)

Penn researchers identify new cost-effective antibiotic treatment which shortens patient stays
University of Pennsylvania Health System researchers and colleagues have concluded that the antibiotic linezolid has the potential to shorten patient stays, while providing hospitals cost-saving benefits when used to treat infections resistant to most other antibiotics that can extend a patient's length of stay. (2001-02-27)

Nabi StaphVAX elicits antibodies with in vitro activity against antibiotic-resistant Staphylococcus aureus strains
Antibodies elicited by Nabi(R) StaphVAX(R), an investigational vaccine to prevent Staphylococcus aureus bacteremias, combat antibiotic resistant as well as antibiotic sensitive strains of the bacteria. In a S. aureus infection model, animals immunized with the vaccine and challenged with representative Vancomycin insensitive strains (VISA strains) were equally protected against infection. (2001-02-21)

Researchers Report Emergence Of Antibiotic Resistance During Vancomycin Therapy
A team of researchers led by The Rockefeller University's Alexander Tomasz, Ph.D., have described the case of a 79- year-old patient whose death in a New York metropolitan area hospital last March was associated with a bloodstream infection caused by a multidrug-resistant strain of Staphylococcus aureus. (1999-02-18)

Drug-Resistant Infection Once Found Only In Hospitals Now Present In Community
Drug-resistant Staphylococcus aureus, a predominantly hospital-acquired infection, has been identified in children outside of the hospital setting with no identified risk factors, according to a study by researchers at the University of Chicago Children's Hospital, published in the February 25 issue of the Journal of the American Medical Association. (1998-02-25)

Hospital-Acquired Antibiotic-Resistant Infections Triple Costs And Lengths Of Hospitalization
Duke University Medical Center researchers have put a price tag on the most common hospital-acquired infections that can prolong and increase the cost of a patient's stay in the hospital. (1997-09-29)

Guidelines Offer Ways To Curb Antibiotic-Resistant Infections
Infections caused by organisms that no longer respond to antibiotics are increasing alarmingly fast in hospitals and health care facilities across the nation, University of North Carolina at Chapel Hill experts say. (1997-05-13)

Page 21 of 21 | 825 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to